Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Buggisch

Showing results (81-90 of 110) with videos related to

Pageof 11
Sort By:
Journal of Hepatology|January 18, 2011
Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis CMichael Manns, Stefan Zeuzem, Ajit Sood, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 18, 2025
Impact of Handling Perception and Language Barriers on Virologic Response to Daily Subcutaneous Bulevirtide in Hepatitis DToni Herta, Christopher Dietz-Fricke, Münevver Demir, et al.
Plos One|October 11, 2014
Treatment of naïve patients with chronic hepatitis C genotypes 2 and 3 with pegylated interferon alpha and ribavirin in a real world setting: relevance for the new era of DAABenjamin Heidrich, Steffen B Wiegand, Peter Buggisch, et al.
Therapeutic Advances in Medical Oncology|October 27, 2025
Treatment gaps and survival outcomes of hepatocellular carcinoma: insights from a nationwide, claims-based studySimone Schrodi, Karin Berger-Thürmel, Selina Becht, et al.
The American Journal of Gastroenterology|September 1, 2021
Ledipasvir/Sofosbuvir for 8, 12, or 24 Weeks in Hepatitis C Patients Undergoing Dialysis for End-Stage Renal DiseaseWan-Long Chuang, Tsung-Hui Hu, Peter Buggisch, et al.
European Journal of Gastroenterology & Hepatology|November 18, 2015
Symptoms of anxiety and depression are frequent in patients with acute hepatitis C and are not associated with disease severityKatja Deterding, Norbert Grüner, Peter Buggisch, et al.
Hepatology (Baltimore, Md.)|January 30, 2019
JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1Stefan Zeuzem, Stefan Bourgeois, Susan Greenbloom, et al.
Annals of Internal Medicine|July 18, 2012
Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trialMartin Schaefer, Rahul Sarkar, Viola Knop, et al.
Antimicrobial Agents and Chemotherapy|August 10, 2016
Preclinical Profile and Clinical Efficacy of a Novel Hepatitis C Virus NS5A Inhibitor, EDP-239Christopher M Owens, Bradley B Brasher, Alex Polemeropoulos, et al.
The Lancet. Infectious Diseases|March 26, 2013
Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trialKatja Deterding, Norbert Grüner, Peter Buggisch, et al.
Pageof 11

Showing results (81-90 of 110) with videos related to

Sort By:
Pageof 11
Journal of Hepatology|January 18, 2011
Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis CMichael Manns, Stefan Zeuzem, Ajit Sood, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 18, 2025
Impact of Handling Perception and Language Barriers on Virologic Response to Daily Subcutaneous Bulevirtide in Hepatitis DToni Herta, Christopher Dietz-Fricke, Münevver Demir, et al.
Plos One|October 11, 2014
Treatment of naïve patients with chronic hepatitis C genotypes 2 and 3 with pegylated interferon alpha and ribavirin in a real world setting: relevance for the new era of DAABenjamin Heidrich, Steffen B Wiegand, Peter Buggisch, et al.
Therapeutic Advances in Medical Oncology|October 27, 2025
Treatment gaps and survival outcomes of hepatocellular carcinoma: insights from a nationwide, claims-based studySimone Schrodi, Karin Berger-Thürmel, Selina Becht, et al.
The American Journal of Gastroenterology|September 1, 2021
Ledipasvir/Sofosbuvir for 8, 12, or 24 Weeks in Hepatitis C Patients Undergoing Dialysis for End-Stage Renal DiseaseWan-Long Chuang, Tsung-Hui Hu, Peter Buggisch, et al.
European Journal of Gastroenterology & Hepatology|November 18, 2015
Symptoms of anxiety and depression are frequent in patients with acute hepatitis C and are not associated with disease severityKatja Deterding, Norbert Grüner, Peter Buggisch, et al.
Hepatology (Baltimore, Md.)|January 30, 2019
JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1Stefan Zeuzem, Stefan Bourgeois, Susan Greenbloom, et al.
Annals of Internal Medicine|July 18, 2012
Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trialMartin Schaefer, Rahul Sarkar, Viola Knop, et al.
Antimicrobial Agents and Chemotherapy|August 10, 2016
Preclinical Profile and Clinical Efficacy of a Novel Hepatitis C Virus NS5A Inhibitor, EDP-239Christopher M Owens, Bradley B Brasher, Alex Polemeropoulos, et al.
The Lancet. Infectious Diseases|March 26, 2013
Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trialKatja Deterding, Norbert Grüner, Peter Buggisch, et al.
Pageof 11